Global Solid Tumor Drugs

Solid Tumor Drugs Comprehensive Study by Type (Small Molecules, Biologics), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others), Drug (Entrectinib, Keytruda (Pembrolizumab), Larotrectinib Sulfate, Pembrolizumab, Rozlytrek (Entrectinib), Vitrakvi (Larotrectinib Sulfate)), Therapy (Chemotherapy, Hormone therapy, Immunotherapy, Targeted therapy) Players and Region - Global Market Outlook to 2026

Solid Tumor Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Solid Tumor Drugs Market Overview:
Solid Tumors are abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid Tumors can be cancerous (malignant) or noncancerous (benign). The global solid tumor drugs market is expected to grow in the future due to advancements in treatment techniques, such as targeted and combination therapies. The rise in the prevalence of different forms of metastatic cancers and the increase in the demand for highly effective chemotherapeutic agents are driving the market.

Growth Drivers
  • Rise in the Prevalence of Different Forms of Metastatic Cancers
  • Increase in the Demand for Highly Effective Chemotherapeutic Agents

Market Trends
  • Increasing Investment in Clinical Trials along with R&D of Cancer Drugs

Roadblocks
  • Side Effects of Solid Tumor Drugs such as Skin Reactions, Anemia, and Hair Loss

Opportunities
  • Increasing Expenditure in Cancer Treatment
  • Growth in the Healthcare Industry Worldwide
  • Rise in the Healthcare Infrastructure in Developing Regions

Challenges
  • High Cost of Therapy
  • Stringent Government Rules and Regulations for New Drug Approval


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are AstraZeneca (United Kingdom), Abbott Laboratories (United States), Amgen Ireland Limited (Ireland), Biogen (United States), Baxter (United States), Bristol-Myers Squibb Company (United States), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly and Company (United States), Johnson & Johnson Services Inc (United States), GlaxoSmithKline PLC (United Kingdom), Celgene Corporation (United States) and Pfizer Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Solid Tumor Drugs market by 2026. Considering Market by Drug, the sub-segment i.e. Entrectinib will boost the Solid Tumor Drugs market. Considering Market by Therapy, the sub-segment i.e. Chemotherapy will boost the Solid Tumor Drugs market.

In Aug 2020, Foundation Medicine, Inc. announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne®Liquid CDx, the Company’s comprehensive pan-tumor liquid biopsy test., and In June 2020, The Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

What Can be Explored with the Solid Tumor Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Solid Tumor Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Solid Tumor Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Solid Tumor Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Solid Tumor Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Solid Tumor Drugs Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Small Molecules
  • Biologics
By Application
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Others
By Drug
  • Entrectinib
  • Keytruda (Pembrolizumab)
  • Larotrectinib Sulfate
  • Pembrolizumab
  • Rozlytrek (Entrectinib)
  • Vitrakvi (Larotrectinib Sulfate)

By Therapy
  • Chemotherapy
  • Hormone therapy
  • Immunotherapy
  • Targeted therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in the Prevalence of Different Forms of Metastatic Cancers
      • 3.2.2. Increase in the Demand for Highly Effective Chemotherapeutic Agents
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Therapy
      • 3.3.2. Stringent Government Rules and Regulations for New Drug Approval
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment in Clinical Trials along with R&D of Cancer Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Solid Tumor Drugs, by Type, Application, Drug, Therapy and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Solid Tumor Drugs (Value)
      • 5.2.1. Global Solid Tumor Drugs by: Type (Value)
        • 5.2.1.1. Small Molecules
        • 5.2.1.2. Biologics
      • 5.2.2. Global Solid Tumor Drugs by: Application (Value)
        • 5.2.2.1. Breast Cancer
        • 5.2.2.2. Lung Cancer
        • 5.2.2.3. Colorectal Cancer
        • 5.2.2.4. Prostate Cancer
        • 5.2.2.5. Cervical Cancer
        • 5.2.2.6. Others
      • 5.2.3. Global Solid Tumor Drugs by: Drug (Value)
        • 5.2.3.1. Entrectinib
        • 5.2.3.2. Keytruda (Pembrolizumab)
        • 5.2.3.3. Larotrectinib Sulfate
        • 5.2.3.4. Pembrolizumab
        • 5.2.3.5. Rozlytrek (Entrectinib)
        • 5.2.3.6. Vitrakvi (Larotrectinib Sulfate)
      • 5.2.4. Global Solid Tumor Drugs by: Therapy (Value)
        • 5.2.4.1. Chemotherapy
        • 5.2.4.2. Hormone therapy
        • 5.2.4.3. Immunotherapy
        • 5.2.4.4. Targeted therapy
      • 5.2.5. Global Solid Tumor Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Solid Tumor Drugs (Price)
      • 5.3.1. Global Solid Tumor Drugs by: Type (Price)
  • 6. Solid Tumor Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen Ireland Limited (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biogen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Baxter (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson & Johnson Services Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Celgene Corporation (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Pfizer Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Solid Tumor Drugs Sale, by Type, Application, Drug, Therapy and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Solid Tumor Drugs (Value)
      • 7.2.1. Global Solid Tumor Drugs by: Type (Value)
        • 7.2.1.1. Small Molecules
        • 7.2.1.2. Biologics
      • 7.2.2. Global Solid Tumor Drugs by: Application (Value)
        • 7.2.2.1. Breast Cancer
        • 7.2.2.2. Lung Cancer
        • 7.2.2.3. Colorectal Cancer
        • 7.2.2.4. Prostate Cancer
        • 7.2.2.5. Cervical Cancer
        • 7.2.2.6. Others
      • 7.2.3. Global Solid Tumor Drugs by: Drug (Value)
        • 7.2.3.1. Entrectinib
        • 7.2.3.2. Keytruda (Pembrolizumab)
        • 7.2.3.3. Larotrectinib Sulfate
        • 7.2.3.4. Pembrolizumab
        • 7.2.3.5. Rozlytrek (Entrectinib)
        • 7.2.3.6. Vitrakvi (Larotrectinib Sulfate)
      • 7.2.4. Global Solid Tumor Drugs by: Therapy (Value)
        • 7.2.4.1. Chemotherapy
        • 7.2.4.2. Hormone therapy
        • 7.2.4.3. Immunotherapy
        • 7.2.4.4. Targeted therapy
      • 7.2.5. Global Solid Tumor Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Solid Tumor Drugs (Price)
      • 7.3.1. Global Solid Tumor Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Solid Tumor Drugs: by Type(USD Million)
  • Table 2. Solid Tumor Drugs Small Molecules , by Region USD Million (2015-2020)
  • Table 3. Solid Tumor Drugs Biologics , by Region USD Million (2015-2020)
  • Table 4. Solid Tumor Drugs: by Application(USD Million)
  • Table 5. Solid Tumor Drugs Breast Cancer , by Region USD Million (2015-2020)
  • Table 6. Solid Tumor Drugs Lung Cancer , by Region USD Million (2015-2020)
  • Table 7. Solid Tumor Drugs Colorectal Cancer , by Region USD Million (2015-2020)
  • Table 8. Solid Tumor Drugs Prostate Cancer , by Region USD Million (2015-2020)
  • Table 9. Solid Tumor Drugs Cervical Cancer , by Region USD Million (2015-2020)
  • Table 10. Solid Tumor Drugs Others , by Region USD Million (2015-2020)
  • Table 11. Solid Tumor Drugs: by Drug(USD Million)
  • Table 12. Solid Tumor Drugs Entrectinib , by Region USD Million (2015-2020)
  • Table 13. Solid Tumor Drugs Keytruda (Pembrolizumab) , by Region USD Million (2015-2020)
  • Table 14. Solid Tumor Drugs Larotrectinib Sulfate , by Region USD Million (2015-2020)
  • Table 15. Solid Tumor Drugs Pembrolizumab , by Region USD Million (2015-2020)
  • Table 16. Solid Tumor Drugs Rozlytrek (Entrectinib) , by Region USD Million (2015-2020)
  • Table 17. Solid Tumor Drugs Vitrakvi (Larotrectinib Sulfate) , by Region USD Million (2015-2020)
  • Table 18. Solid Tumor Drugs: by Therapy(USD Million)
  • Table 19. Solid Tumor Drugs Chemotherapy , by Region USD Million (2015-2020)
  • Table 20. Solid Tumor Drugs Hormone therapy , by Region USD Million (2015-2020)
  • Table 21. Solid Tumor Drugs Immunotherapy , by Region USD Million (2015-2020)
  • Table 22. Solid Tumor Drugs Targeted therapy , by Region USD Million (2015-2020)
  • Table 23. South America Solid Tumor Drugs, by Country USD Million (2015-2020)
  • Table 24. South America Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 25. South America Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 26. South America Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 27. South America Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 28. Brazil Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 29. Brazil Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 30. Brazil Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 31. Brazil Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 32. Argentina Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 33. Argentina Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 34. Argentina Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 35. Argentina Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 36. Rest of South America Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 37. Rest of South America Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 38. Rest of South America Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 39. Rest of South America Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 40. Asia Pacific Solid Tumor Drugs, by Country USD Million (2015-2020)
  • Table 41. Asia Pacific Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 42. Asia Pacific Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 43. Asia Pacific Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 44. Asia Pacific Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 45. China Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 46. China Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 47. China Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 48. China Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 49. Japan Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 50. Japan Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 51. Japan Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 52. Japan Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 53. India Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 54. India Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 55. India Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 56. India Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 57. South Korea Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 58. South Korea Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 59. South Korea Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 60. South Korea Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 61. Taiwan Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 62. Taiwan Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 63. Taiwan Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 64. Taiwan Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 65. Australia Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 66. Australia Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 67. Australia Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 68. Australia Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 73. Europe Solid Tumor Drugs, by Country USD Million (2015-2020)
  • Table 74. Europe Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 75. Europe Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 76. Europe Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 77. Europe Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 78. Germany Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 79. Germany Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 80. Germany Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 81. Germany Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 82. France Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 83. France Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 84. France Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 85. France Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 86. Italy Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 87. Italy Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 88. Italy Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 89. Italy Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 90. United Kingdom Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 91. United Kingdom Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 92. United Kingdom Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 93. United Kingdom Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 94. Netherlands Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 95. Netherlands Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 96. Netherlands Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 97. Netherlands Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 98. Rest of Europe Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 99. Rest of Europe Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 100. Rest of Europe Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 101. Rest of Europe Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 102. MEA Solid Tumor Drugs, by Country USD Million (2015-2020)
  • Table 103. MEA Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 104. MEA Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 105. MEA Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 106. MEA Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 107. Middle East Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 108. Middle East Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 109. Middle East Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 110. Middle East Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 111. Africa Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 112. Africa Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 113. Africa Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 114. Africa Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 115. North America Solid Tumor Drugs, by Country USD Million (2015-2020)
  • Table 116. North America Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 117. North America Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 118. North America Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 119. North America Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 120. United States Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 121. United States Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 122. United States Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 123. United States Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 124. Canada Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 125. Canada Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 126. Canada Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 127. Canada Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 128. Mexico Solid Tumor Drugs, by Type USD Million (2015-2020)
  • Table 129. Mexico Solid Tumor Drugs, by Application USD Million (2015-2020)
  • Table 130. Mexico Solid Tumor Drugs, by Drug USD Million (2015-2020)
  • Table 131. Mexico Solid Tumor Drugs, by Therapy USD Million (2015-2020)
  • Table 132. Solid Tumor Drugs: by Type(USD/Units)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Solid Tumor Drugs: by Type(USD Million)
  • Table 146. Solid Tumor Drugs Small Molecules , by Region USD Million (2021-2026)
  • Table 147. Solid Tumor Drugs Biologics , by Region USD Million (2021-2026)
  • Table 148. Solid Tumor Drugs: by Application(USD Million)
  • Table 149. Solid Tumor Drugs Breast Cancer , by Region USD Million (2021-2026)
  • Table 150. Solid Tumor Drugs Lung Cancer , by Region USD Million (2021-2026)
  • Table 151. Solid Tumor Drugs Colorectal Cancer , by Region USD Million (2021-2026)
  • Table 152. Solid Tumor Drugs Prostate Cancer , by Region USD Million (2021-2026)
  • Table 153. Solid Tumor Drugs Cervical Cancer , by Region USD Million (2021-2026)
  • Table 154. Solid Tumor Drugs Others , by Region USD Million (2021-2026)
  • Table 155. Solid Tumor Drugs: by Drug(USD Million)
  • Table 156. Solid Tumor Drugs Entrectinib , by Region USD Million (2021-2026)
  • Table 157. Solid Tumor Drugs Keytruda (Pembrolizumab) , by Region USD Million (2021-2026)
  • Table 158. Solid Tumor Drugs Larotrectinib Sulfate , by Region USD Million (2021-2026)
  • Table 159. Solid Tumor Drugs Pembrolizumab , by Region USD Million (2021-2026)
  • Table 160. Solid Tumor Drugs Rozlytrek (Entrectinib) , by Region USD Million (2021-2026)
  • Table 161. Solid Tumor Drugs Vitrakvi (Larotrectinib Sulfate) , by Region USD Million (2021-2026)
  • Table 162. Solid Tumor Drugs: by Therapy(USD Million)
  • Table 163. Solid Tumor Drugs Chemotherapy , by Region USD Million (2021-2026)
  • Table 164. Solid Tumor Drugs Hormone therapy , by Region USD Million (2021-2026)
  • Table 165. Solid Tumor Drugs Immunotherapy , by Region USD Million (2021-2026)
  • Table 166. Solid Tumor Drugs Targeted therapy , by Region USD Million (2021-2026)
  • Table 167. South America Solid Tumor Drugs, by Country USD Million (2021-2026)
  • Table 168. South America Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 169. South America Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 170. South America Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 171. South America Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 172. Brazil Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 173. Brazil Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 174. Brazil Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 175. Brazil Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 176. Argentina Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 177. Argentina Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 178. Argentina Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 179. Argentina Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 180. Rest of South America Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 181. Rest of South America Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 182. Rest of South America Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 183. Rest of South America Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 184. Asia Pacific Solid Tumor Drugs, by Country USD Million (2021-2026)
  • Table 185. Asia Pacific Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 186. Asia Pacific Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 187. Asia Pacific Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 188. Asia Pacific Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 189. China Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 190. China Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 191. China Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 192. China Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 193. Japan Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 194. Japan Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 195. Japan Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 196. Japan Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 197. India Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 198. India Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 199. India Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 200. India Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 201. South Korea Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 202. South Korea Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 203. South Korea Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 204. South Korea Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 205. Taiwan Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 206. Taiwan Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 207. Taiwan Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 208. Taiwan Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 209. Australia Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 210. Australia Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 211. Australia Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 212. Australia Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 214. Rest of Asia-Pacific Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 215. Rest of Asia-Pacific Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 216. Rest of Asia-Pacific Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 217. Europe Solid Tumor Drugs, by Country USD Million (2021-2026)
  • Table 218. Europe Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 219. Europe Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 220. Europe Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 221. Europe Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 222. Germany Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 223. Germany Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 224. Germany Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 225. Germany Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 226. France Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 227. France Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 228. France Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 229. France Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 230. Italy Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 231. Italy Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 232. Italy Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 233. Italy Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 234. United Kingdom Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 235. United Kingdom Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 236. United Kingdom Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 237. United Kingdom Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 238. Netherlands Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 239. Netherlands Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 240. Netherlands Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 241. Netherlands Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 242. Rest of Europe Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 243. Rest of Europe Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 244. Rest of Europe Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 245. Rest of Europe Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 246. MEA Solid Tumor Drugs, by Country USD Million (2021-2026)
  • Table 247. MEA Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 248. MEA Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 249. MEA Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 250. MEA Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 251. Middle East Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 252. Middle East Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 253. Middle East Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 254. Middle East Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 255. Africa Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 256. Africa Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 257. Africa Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 258. Africa Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 259. North America Solid Tumor Drugs, by Country USD Million (2021-2026)
  • Table 260. North America Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 261. North America Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 262. North America Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 263. North America Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 264. United States Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 265. United States Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 266. United States Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 267. United States Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 268. Canada Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 269. Canada Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 270. Canada Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 271. Canada Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 272. Mexico Solid Tumor Drugs, by Type USD Million (2021-2026)
  • Table 273. Mexico Solid Tumor Drugs, by Application USD Million (2021-2026)
  • Table 274. Mexico Solid Tumor Drugs, by Drug USD Million (2021-2026)
  • Table 275. Mexico Solid Tumor Drugs, by Therapy USD Million (2021-2026)
  • Table 276. Solid Tumor Drugs: by Type(USD/Units)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Solid Tumor Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Solid Tumor Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Solid Tumor Drugs: by Drug USD Million (2015-2020)
  • Figure 7. Global Solid Tumor Drugs: by Therapy USD Million (2015-2020)
  • Figure 8. South America Solid Tumor Drugs Share (%), by Country
  • Figure 9. Asia Pacific Solid Tumor Drugs Share (%), by Country
  • Figure 10. Europe Solid Tumor Drugs Share (%), by Country
  • Figure 11. MEA Solid Tumor Drugs Share (%), by Country
  • Figure 12. North America Solid Tumor Drugs Share (%), by Country
  • Figure 13. Global Solid Tumor Drugs: by Type USD/Units (2015-2020)
  • Figure 14. Global Solid Tumor Drugs share by Players 2020 (%)
  • Figure 15. Global Solid Tumor Drugs share by Players (Top 3) 2020(%)
  • Figure 16. Global Solid Tumor Drugs share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 20. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 22. Amgen Ireland Limited (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Amgen Ireland Limited (Ireland) Revenue: by Geography 2020
  • Figure 24. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 25. Biogen (United States) Revenue: by Geography 2020
  • Figure 26. Baxter (United States) Revenue, Net Income and Gross profit
  • Figure 27. Baxter (United States) Revenue: by Geography 2020
  • Figure 28. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 30. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 32. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 34. Johnson & Johnson Services Inc (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson & Johnson Services Inc (United States) Revenue: by Geography 2020
  • Figure 36. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 38. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 39. Celgene Corporation (United States) Revenue: by Geography 2020
  • Figure 40. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 42. Global Solid Tumor Drugs: by Type USD Million (2021-2026)
  • Figure 43. Global Solid Tumor Drugs: by Application USD Million (2021-2026)
  • Figure 44. Global Solid Tumor Drugs: by Drug USD Million (2021-2026)
  • Figure 45. Global Solid Tumor Drugs: by Therapy USD Million (2021-2026)
  • Figure 46. South America Solid Tumor Drugs Share (%), by Country
  • Figure 47. Asia Pacific Solid Tumor Drugs Share (%), by Country
  • Figure 48. Europe Solid Tumor Drugs Share (%), by Country
  • Figure 49. MEA Solid Tumor Drugs Share (%), by Country
  • Figure 50. North America Solid Tumor Drugs Share (%), by Country
  • Figure 51. Global Solid Tumor Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Abbott Laboratories (United States)
  • Amgen Ireland Limited (Ireland)
  • Biogen (United States)
  • Baxter (United States)
  • Bristol-Myers Squibb Company (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Eli Lilly and Company (United States)
  • Johnson & Johnson Services Inc (United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Celgene Corporation (United States)
  • Pfizer Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2021 249 Pages 95 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Solid Tumor Drugs Quantitative research analysis
Global Solid Tumor Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Solid Tumor Drugs Report?

Have a Query? Click Here

Other Related Reports

Reishi Mushroom Supplements Comprehensive Study by End User Industries (Food & Beverage, Healthcare, Personal Care), Form (Liquid Extract, Powder Extract), Product (Organic Reishi Mushroom Extract, C...
$ 3450
Anti Ageing Ingredients Comprehensive Study by Type (Chemical Peels, Sunscreen Ingredients, Peptides, Hyaluronic Acid, Anti-Oxidants, Retinol, Niacinamide, Others), Application (Cosmetics, Food & Bev...
$ 3350
Heparin Injection Comprehensive Study by Type (1,000 USP/mL, 5,000 USP/mL, 10,000 USP/mL, 20,000 USP/mL), Application (Thrombosis,, Pulmonary Embolism, Hemodialysis, Others), Heparin Type (Unfraction...
$ 3650
Opioid Use Disorder Comprehensive Study by Application (Moderate Pain Treatment, Severe Pain Treatment), Drug (Buprenorphine (Bunavail) Players and Region - Global Market Outlook to 2026
$ 3500
Esophageal Cancer Drugs Comprehensive Study by Type (Carboplatin, Oxaliplatin, Cisplatin, Paclitaxel), Application (Hospitals, Cancer Clinics), End- User (Men, Women) Players and Region - Global Mark...
$ 3500
Antirheumatics Pharmaceutical Comprehensive Study by Type (Non-Steroidal Anti-Inflammatory Drugs, Steroidal Anti-Inflammatory Drugs, Slow Acting Drug, Immunological Preparation), Application (Pharmac...
$ 3750